A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too
On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc.
Eli Lilly & Co (LLY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 5,063,516 | $6,073,333,633 | +5% | 1.81% |
| 2. | 2,349,200 | $2,817,700,956 | +49% | 0.32% | |
| 3. | 1,881,500 | $2,256,727,545 | +10% | 0.26% | |
| 4. | AQR Capital Management Cliff Asness | 1,035,605 | $1,242,135,647 | +22% | 0.43% |
| 5. | Citadel Investment Group Ken Griffin | 945,456 | $1,134,008,290 | +292% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $691.79 | 715 | $494,626.99 | 14,685 | 2025-08-15 | Filing | |
| $660.25 | 758 | $500,472.53 | 758 | 2025-08-13 | Filing | |
| $647.36 | 1,000 | $647,360.00 | 20,562 | 2025-08-13 | Filing | |
| $644.77 | 1,632 | $1,052,263.01 | 546,601 | 2025-08-12 | Filing | |
| $634.41 | 1,000 | $634,405.00 | 137,660 | 2025-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1,175.10 | 6,500 | $7,638,150.00 | 54,147 | 2026-08-17 | Filing | |
| $1,185.01 | 2,000 | $2,370,020.00 | 1,526 | 2026-08-10 | Filing | |
| $1,190.00 | 5,000 | $5,950,000.00 | 11,875 | 2026-08-07 | Filing | |
| $1,150.77 | 2,500 | $2,876,925.00 | 29,804 | 2026-06-10 | Filing | |
| $996.18 | 2,208 | $2,199,572.06 | 91,881,150 | 2026-05-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 90,376,978 | $108,400,858,723 | 100% | |
| 2. | 67,540,400 | $81,009,980,560 | 1.2% | |
| 3. | 53,528,868 | $64,204,130,146 | 1.37% | |
| 4. | 51,304,828 | $61,536,549,849 | 30.5% | |
| 5. | 36,215,754 | $43,438,261,820 | 1.29% |
News See All
Eli Lilly (LLY) Gets a Big Price Target Boost, Analysts See 20% Upside
On September 15, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from $1,220 to $1,400.
Novo Nordisk (NVO) and Eli Lilly (LLY)'s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, though far less than at full recommended doses...
Novo (NVO) Partners with Anthropic on AI Drug Discoveries
The pharma giant recently rebranded itself.
3 Healthcare Stocks with More Than 20% Upside and Recent Buy Ratings
Eli Lilly ($LLY), UnitedHealth Group ($UNH), and Intuitive Surgical ($ISRG) have each received Buy ratings from Wall Street analysts on September 1...
Billionaire Ray Dalio’s Bridgewater's and Cathie Wood’s ARK Portfolios: 2 Stocks They Both Own
Billionaire Ray Dalio’s Bridgewater Associates and Cathie Wood’s ARK Invest follow sharply different investment philosophies.
Eli Lilly Stock (LLY) Gets New Buy Rating as Weight-Loss Drug Sales Accelerate
The pharma giant is the dominant player in the obesity drug space.
Novo Nordisk Stock (NVO) Is Falling Despite Rebrand to ‘Novo’ — Here’s Why
Novo Nordisk shares ($NVO) fell by 1% to around $43 per share early Tuesday. This came even after the popular obesity drugmaker rebranded simply to...
Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market
Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S.
Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup
The company has a 60% share of the weight-loss drug market.
Hedge Fund Resource Center